Daniel L Faden1,2, Fernando Concha-Benavente3,4, Anish B Chakka5, Elizabeth L McMichael3, Uma Chandran5, Robert L Ferris3,4,6. 1. Department of Otolaryngology, Division of Head and Neck Surgical Oncology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 5. Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Mechanisms of resistance to immune-modulating cancer treatments are poorly understood. Using a novel cohort of patients with head and neck squamous cell carcinoma (HNSCC), we investigated mechanisms of immune escape from epidermal growth factor receptor-specific monoclonal antibody (mAb) therapy. METHODS: HNSCC tumors (n = 20) from a prospective trial of neoadjuvant cetuximab monotherapy underwent whole-exome sequencing. Expression of killer-cell immunoglobulin-like receptor (KIR) and human leukocyte antigen-C (HLA-C) and the effect of KIR blockade were assessed in HNSCC cell lines. RESULTS: Nonresponders to cetuximab had an increased rate of mutations in HLA-C compared to responders and HNSCC tumors (n = 528) in The Cancer Genome Atlas (P < 0.00001). In vitro, cetuximab-activated natural killer (NK) cells induced upregulation of HLA-C on HNSCC cells (P < 0.01) via interferon gamma. Treatment of NK cells with the anti-KIR mAb lirilumab increased killing of HNSCC cells (P < 0.001). CONCLUSIONS: Alterations in HLA-C may provide a mechanism of immune evasion through disruption of NK activation.
BACKGROUND: Mechanisms of resistance to immune-modulating cancer treatments are poorly understood. Using a novel cohort of patients with head and neck squamous cell carcinoma (HNSCC), we investigated mechanisms of immune escape from epidermal growth factor receptor-specific monoclonal antibody (mAb) therapy. METHODS:HNSCC tumors (n = 20) from a prospective trial of neoadjuvant cetuximab monotherapy underwent whole-exome sequencing. Expression of killer-cell immunoglobulin-like receptor (KIR) and human leukocyte antigen-C (HLA-C) and the effect of KIR blockade were assessed in HNSCC cell lines. RESULTS: Nonresponders to cetuximab had an increased rate of mutations in HLA-C compared to responders and HNSCC tumors (n = 528) in The Cancer Genome Atlas (P < 0.00001). In vitro, cetuximab-activated natural killer (NK) cells induced upregulation of HLA-C on HNSCC cells (P < 0.01) via interferon gamma. Treatment of NK cells with the anti-KIRmAb lirilumab increased killing of HNSCC cells (P < 0.001). CONCLUSIONS: Alterations in HLA-C may provide a mechanism of immune evasion through disruption of NK activation.
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Elizabeth L McMichael; Alena Cristina Jaime-Ramirez; Kristan D Guenterberg; Eric Luedke; Lakhvir S Atwal; Amanda R Campbell; Zhiwei Hu; Armika S Tatum; Sri Vidya Kondadasula; Xiaokui Mo; Susheela Tridandapani; Mark Bloomston; E Christopher Ellison; Terence M Williams; Tanios Bekaii-Saab; William E Carson Journal: Clin Cancer Res Date: 2016-07-19 Impact factor: 12.531
Authors: H Ikeda; B Lethé; F Lehmann; N van Baren; J F Baurain; C de Smet; H Chambost; M Vitale; A Moretta; T Boon; P G Coulie Journal: Immunity Date: 1997-02 Impact factor: 31.745
Authors: Steve C Lee; Raghvendra M Srivastava; Andrés López-Albaitero; Soldano Ferrone; Robert L Ferris Journal: Immunol Res Date: 2011-08 Impact factor: 2.829
Authors: Vassiliki Saloura; Ezra E W Cohen; Lisa Licitra; Salem Billan; Jose Dinis; Steen Lisby; Thomas C Gauler Journal: Cancer Chemother Pharmacol Date: 2014-04-09 Impact factor: 3.333
Authors: S Trivedi; F Concha-Benavente; R M Srivastava; H B Jie; S P Gibson; N C Schmitt; R L Ferris Journal: Ann Oncol Date: 2014-07-04 Impact factor: 32.976
Authors: Sumita Trivedi; Raghvendra M Srivastava; Fernando Concha-Benavente; Soldano Ferrone; Tatiana M Garcia-Bates; Jing Li; Robert L Ferris Journal: Clin Cancer Res Date: 2016-05-23 Impact factor: 12.531
Authors: John Pradeep Veluchamy; Jan Spanholtz; Marleen Tordoir; Victor L Thijssen; Daniëlle A M Heideman; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet Journal: PLoS One Date: 2016-06-17 Impact factor: 3.240
Authors: Barbara Manzanares-Martin; Arancha Cebrián Aranda; Laura Del Puerto-Nevado; Rafael González; Sonia Solanes; Maria Auxiliadora Gómez-España; Jesús García-Foncillas; Enrique Aranda Journal: J Immunother Cancer Date: 2021-04 Impact factor: 13.751
Authors: Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters Journal: Front Immunol Date: 2021-09-07 Impact factor: 7.561
Authors: Julie E Bauman; James Ohr; William E Gooding; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Adam C Soloff; Gerald Wallweber; John Winslow; Autumn Gaither-Davis; Jennifer R Grandis; Laura P Stabile Journal: Cancers (Basel) Date: 2020-06-11 Impact factor: 6.639